These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 11044171)
1. Effect of surgical subspecialization on breast cancer outcome. Golledge J; Wiggins JE; Callam MJ Br J Surg; 2000 Oct; 87(10):1420-5. PubMed ID: 11044171 [TBL] [Abstract][Full Text] [Related]
2. Breast cancer recurrences in elderly patients after lumpectomy. Shah S; Doyle K; Lange EM; Shen P; Pennell T; Ferree C; Levine EA; Perrier ND Am Surg; 2002 Aug; 68(8):735-9. PubMed ID: 12206612 [TBL] [Abstract][Full Text] [Related]
3. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. Hillner BE Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322 [TBL] [Abstract][Full Text] [Related]
4. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T; Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060 [TBL] [Abstract][Full Text] [Related]
5. Improving local control with breast-conserving therapy: a 27-year single-institution experience. Cabioglu N; Hunt KK; Buchholz TA; Mirza N; Singletary SE; Kuerer HM; Babiera GV; Ames FC; Sahin AA; Meric-Bernstam F Cancer; 2005 Jul; 104(1):20-9. PubMed ID: 15912514 [TBL] [Abstract][Full Text] [Related]
6. Survival and breast relapse in 3834 patients with T1-T2 breast cancer after conserving surgery and adjuvant treatment. Livi L; Paiar F; Saieva C; Scoccianti S; Dicosmo D; Borghesi S; Agresti B; Nosi F; Orzalesi L; Santini R; Barca R; Biti GP Radiother Oncol; 2007 Mar; 82(3):287-93. PubMed ID: 17188382 [TBL] [Abstract][Full Text] [Related]
7. Improved survival for women with stage I breast cancer in south-east Sweden: a comparison between two time periods before and after increased use of adjuvant systemic therapy. Johansson P; Fohlin H; Arnesson LG; Dufmats M; Nordenskjöld K; Nordenskjöld B; Stål O; Acta Oncol; 2009; 48(4):504-13. PubMed ID: 19235568 [TBL] [Abstract][Full Text] [Related]
8. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group. Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ; Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892 [TBL] [Abstract][Full Text] [Related]
9. Randomized trial of 2 versus 5 years of adjuvant tamoxifen for women aged 50 years or older with early breast cancer: Italian Interdisciplinary Group Cancer Evaluation Study of Adjuvant Treatment in Breast Cancer 01. Sacco M; Valentini M; Belfiglio M; Pellegrini F; De Berardis G; Franciosi M; Nicolucci A; J Clin Oncol; 2003 Jun; 21(12):2276-81. PubMed ID: 12805326 [TBL] [Abstract][Full Text] [Related]
10. [Locally advanced non inflammatory breast cancer treated by combined chemotherapy and preoperative irradiation: updated results in a series of 120 patients]. Lerouge D; Touboul E; Lefranc JP; Genestie C; Moureau-Zabotto L; Blondon J Cancer Radiother; 2004 Jun; 8(3):155-67. PubMed ID: 15217583 [TBL] [Abstract][Full Text] [Related]
11. Use of tamoxifen in pT1a-pT1b, pN0 breast cancer. Livi L; Saieva C; Paiar F; Simontacchi G; Galardi A; De Luca Cardillo C; Mangoni M; Paoletti L; Ponticelli P; Biti GP Eur J Surg Oncol; 2007 Apr; 33(3):271-5. PubMed ID: 16831531 [TBL] [Abstract][Full Text] [Related]
12. Late follow-up of a randomized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer. Fennessy M; Bates T; MacRae K; Riley D; Houghton J; Baum M Br J Surg; 2004 Jun; 91(6):699-704. PubMed ID: 15164437 [TBL] [Abstract][Full Text] [Related]
13. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials. Fisher B; Jeong JH; Anderson S; Wolmark N J Natl Cancer Inst; 2004 Dec; 96(24):1823-31. PubMed ID: 15601638 [TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046 [TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582 [TBL] [Abstract][Full Text] [Related]
16. Profile of prognostic factors in 1022 Indian women with early-stage breast cancer treated with breast-conserving therapy. Dinshaw KA; Budrukkar AN; Chinoy RF; Sarin R; Badwe R; Hawaldar R; Shrivastava SK Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1132-41. PubMed ID: 15978744 [TBL] [Abstract][Full Text] [Related]
17. Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IV. Crivellari D; Price K; Gelber RD; Castiglione-Gertsch M; Rudenstam CM; Lindtner J; Fey MF; Senn HJ; Coates AS; Collins J; Goldhirsch A; J Clin Oncol; 2003 Dec; 21(24):4517-23. PubMed ID: 14673038 [TBL] [Abstract][Full Text] [Related]
18. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM; J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968 [TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy in stage III breast cancer. Alassas M; Chu Q; Burton G; Ampil F; Mizell J; Li BD Am Surg; 2005 Jun; 71(6):487-92. PubMed ID: 16044927 [TBL] [Abstract][Full Text] [Related]
20. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. Trimbos JB; Vergote I; Bolis G; Vermorken JB; Mangioni C; Madronal C; Franchi M; Tateo S; Zanetta G; Scarfone G; Giurgea L; Timmers P; Coens C; Pecorelli S; J Natl Cancer Inst; 2003 Jan; 95(2):113-25. PubMed ID: 12529344 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]